Detalhe da pesquisa
1.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216247
2.
Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults.
J Transl Med
; 16(1): 153, 2018 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866115
3.
Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.
J Virol
; 90(22): 10133-10144, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27581989
4.
An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice.
Immun Ageing
; 9(1): 21, 2012 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23031690
5.
Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.
J Immunother
; 45(3): 167-179, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034046
6.
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Cancer Treat Res Commun
; 28: 100405, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329846
7.
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Clin Transl Sci
; 14(1): 277-287, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32770720
8.
Antibody and B cell responses to an investigational adjuvanted RSV vaccine for older adults.
Hum Vaccin Immunother
; 15(10): 2466-2474, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30852939
9.
Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay.
Clin Vaccine Immunol
; 24(12)2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29021302
10.
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
Clin Vaccine Immunol
; 24(9)2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28679495
11.
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Vaccine
; 34(25): 2847-54, 2016 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27102821
12.
Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.
Vaccine
; 33(36): 4472-8, 2015 Aug 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26206269
13.
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
PLoS One
; 10(3): e0119509, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25793508
14.
Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.
Clin Vaccine Immunol
; 21(5): 628-35, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24574540
15.
Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.
PLoS One
; 7(8): e42610, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22880054
16.
Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A.
PLoS One
; 7(12): e51618, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23284726
17.
Tumor-derived variants of Epstein-Barr virus latent membrane protein 1 induce sustained Erk activation and c-Fos.
J Biol Chem
; 283(52): 36573-85, 2008 Dec 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-18986987
18.
Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10.
J Immunol
; 179(12): 8225-34, 2007 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18056366
19.
EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis.
J Immunol
; 177(5): 3283-93, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16920969
20.
TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
J Immunol
; 172(2): 929-36, 2004 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14707065